ImmunoGen announced the presentation of new clinical data with the company's targeted anticancer compound, IMGN901. The data were from a Phase I clinical study assessing IMGN901 used in combination with lenalidomide and dexamethasone to treat patients with CD56-expressing relapsed or relapsed/refractory multiple myeloma. The data were reported in an oral presentation at the 54th American Society of Hematology, or ASH, Annual Meeting and Exposition in Atlanta, Georgia.
Happy demi-anniversary, stock market rally. Will the honeymoon ever end?